[1]
|
Butnariu, L.I., Tarca, E., Cojocaru, E., et al. (2021) Genetic Modifying Factors of Cystic Fibrosis Phenotype: A Challenge for Modern Medicine. Journal of Clinical Medicine, 10, Article 5821. https://doi.org/10.3390/jcm10245821
|
[2]
|
Guo, X., Liu, K., Liu, Y., et al. (2018) Clinical and Genetic Characteristics of Cystic Fibrosis in CHINESE Patients: A Systemic Review of Reported Cases. Orphanet Journal of Rare Diseases, 13, Article No. 224. https://doi.org/10.1186/s13023-018-0968-2
|
[3]
|
Burke, W., Aitken, M.L., Chen, S.H., et al. (1992) Variable Severity of Pulmonary Disease in Adults with Identical Cystic Fibrosis Mutations. Chest, 102, 506-509. https://doi.org/10.1378/chest.102.2.506
|
[4]
|
Mckone, E.F., Emerson, S.S., Edwards, K.L., et al. (2003) Effect of Genotype on Phenotype and Mortality in Cystic Fibrosis: A Retrospective Cohort Study. The Lancet, 361, 1671-1676. https://doi.org/10.1016/S0140-6736(03)13368-5
|
[5]
|
Blackman, S.M., Deering-Brose, R., Mcwilliams, R., et al. (2006) Relative Contribution of Genetic and Nongenetic Modifiers to Intestinal Obstruction in Cystic Fibrosis. Gastroenterology, 131, 1030-1039. https://doi.org/10.1053/j.gastro.2006.07.016
|
[6]
|
Sepahzad, A., Morris-Rosendahl, D.J. and Davies, J.C. (2021) Cystic Fibrosis Lung Disease Modifiers and Their Relevance in the New Era of Precision Medicine. Genes, 12, Article 562. https://doi.org/10.3390/genes12040562
|
[7]
|
Buranawuti, K., Boyle, M.P., Cheng, S., et al. (2007) Variants in Mannose-Binding Lectin and Tumour Necrosis Factor Alpha Affect Survival in Cystic Fibrosis. Journal of Medical Genetics, 44, 209-214. https://doi.org/10.1136/jmg.2006.046318
|
[8]
|
Strug, L.J., Gonska, T., He, G., et al. (2016) Cystic Fibrosis Gene Modifier SLC26A9 Modulates Airway Response to CFTR-Directed Therapeutics. Human Molecular Genetics, 25, 4590-4600. https://doi.org/10.1093/hmg/ddw290
|
[9]
|
林霖, 王岩, 吴传斌, 等. 囊性纤维化及其治疗方法的研究进展[J]. 药学学报, 2022, 57(7): 2024-2031.
|
[10]
|
Gibson, R.L., Burns, J.L. and Ramsey, B.W. (2003) Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 168, 918-951. https://doi.org/10.1164/rccm.200304-505SO
|
[11]
|
Stahl, M., Steinke, E. and Mall, M.A. (2021) Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis. Genes, 12, Article 803. https://doi.org/10.3390/genes12060803
|
[12]
|
Shen, Y., Liu, J., Zhong, L., et al. (2016) Clinical Phenotypes and Genotypic Spectrum of Cystic Fibrosis in Chinese Children. The Journal of Pediatrics, 171, 269-76. e1. https://doi.org/10.1016/j.jpeds.2015.12.025
|
[13]
|
Cutting, G.R. (2015) Cystic Fibrosis Genetics: From Molecular Understanding to Clinical Application. Nature Reviews Genetics, 16, 45-56. https://doi.org/10.1038/nrg3849
|
[14]
|
O’neal, W.K. and Knowles, M.R. (2018) Cystic Fibrosis Disease Modifiers: Complex Genetics Defines the Phenotypic Diversity in a Monogenic Disease. Annual Review of Genomics and Human Genetics, 19, 201-222. https://doi.org/10.1146/annurev-genom-083117-021329
|
[15]
|
Santis, G., Osborne, L., Knight, R.A., et al. (1990) Independent Genetic Determinants of Pancreatic and Pulmonary Status in Cystic Fibrosis. The Lancet, 336, 1081-1084. https://doi.org/10.1016/0140-6736(90)92566-Z
|
[16]
|
Rowntree, R.K. and Harris, A. (2003) The Phenotypic Consequences of CFTR Mutations. Annals of Human Genetics, 67, 471-485. https://doi.org/10.1046/j.1469-1809.2003.00028.x
|
[17]
|
Mésinèle, J., Ruffin, M., Guillot, L., et al. (2022) Modifier Factors of Cystic Fibrosis Phenotypes: A Focus on Modifier Genes. International Journal of Molecular Sciences, 23, Article 14205. https://doi.org/10.3390/ijms232214205
|
[18]
|
Marson, F.A.L. (2018) Disease-Modifying Genetic Factors in Cystic Fibrosis. Current Opinion in Pulmonary Medicine, 24, 296-308. https://doi.org/10.1097/MCP.0000000000000479
|
[19]
|
(2000) Erratum: EUROGAPPP PROJECT 1999-2000 Public and Professional Policy Committee (PPPC)* Population Genetic Screening Programmes: Proposed Recommendations of the European Society of Human Genetics. European Journal of Human Genetics, 8, 998-1000. https://doi.org/10.1038/sj.ejhg.5200587
|
[20]
|
Cutting, G.R. (2006) Causes of Variation in the Cystic Fibrosis Phenotype. Annales Nestlé (English Ed.), 64, 111-117. https://doi.org/10.1159/000095375
|
[21]
|
Barrio, R. (2015) Management of Endocrine Disease: Cystic Fibrosis-Related Diabetes: Novel Pathogenic Insights Opening New Therapeutic Avenues. European Journal of Endocrinology, 172, R131-R141. https://doi.org/10.1530/EJE-14-0644
|
[22]
|
Vanscoy, L.L., Blackman, S.M., Collaco, J.M., et al. (2007) Heritability of Lung Disease Severity in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 175, 1036-1043. https://doi.org/10.1164/rccm.200608-1164OC
|
[23]
|
Flamant, C., Henrion-Caude, A., Boëlle, P.Y., et al. (2004) Glutathione-S-Transferase M1, M3, P1 and T1 Polymorphisms and Severity of Lung Disease in Children with Cystic Fibrosis. Pharmacogenetics, 14, 295-301. https://doi.org/10.1097/00008571-200405000-00004
|
[24]
|
Feuillet-Fieux, M.N., Nguyen-Khoa, T., Loriot, M.A., et al. (2009) Glutathione S-Transferases Related to P. aeruginosa Lung Infection in Cystic Fibrosis Children: Preliminary Study. Clinical Biochemistry, 42, 57-63. https://doi.org/10.1016/j.clinbiochem.2008.09.116
|
[25]
|
Drumm, M.L., Konstan, M.W., Schluchter, M.D., et al. (2005) Genetic Modifiers of Lung Disease in Cystic Fibrosis. The New England Journal of Medicine, 353, 1443-1453. https://doi.org/10.1056/NEJMoa051469
|
[26]
|
Arkwright, P.D., Laurie, S., Super, M., et al. (2000) TGF-β1 Genotype and Accelerated Decline in Lung Function of Patients with Cystic Fibrosis. Thorax, 55, 459-462. https://doi.org/10.1136/thorax.55.6.459
|
[27]
|
Trojan, T., Alejandre Alcazar, M.A., Fink, G., et al. (2022) The Effect of TGF-β(1) Polymorphisms on Pulmonary Disease Progression in Patients with Cystic Fibrosis. BMC Pulmonary Medicine, 22, Article No. 183. https://doi.org/10.1186/s12890-022-01977-1
|
[28]
|
Collaco, J.M., Vanscoy, L., Bremer, L., et al. (2008) Interactions between Secondhand Smoke and Genes That Affect Cystic Fibrosis Lung Disease. JAMA, 299, 417-424. https://doi.org/10.1001/jama.299.4.417
|
[29]
|
Nourkami-Tutdibi, N., Freitag, K., Zemlin, M., et al. (2021) Genetic Association with Pseudomonas aeruginosa Acquisition in Cystic Fibrosis: Influence of Surfactant Protein D and Mannose-Binding Lectin. Frontiers in Immunology, 12, Article 587313. https://doi.org/10.3389/fimmu.2021.587313
|
[30]
|
Turner, M.W. (2003) The Role of Mannose-Binding Lectin in Health and Disease. Molecular Immunology, 40, 423-429. https://doi.org/10.1016/S0161-5890(03)00155-X
|
[31]
|
Chalmers, J.D., Fleming, G.B., Hill, A.T., et al. (2011) Impact of Mannose-Binding Lectin Insufficiency on the Course of Cystic Fibrosis: A Review and Meta-Analysis. Glycobiology, 21, 271-282. https://doi.org/10.1093/glycob/cwq161
|
[32]
|
Pinto, M.C., Quaresma, M.C., Silva, I.A.L., et al. (2021) Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9. International Journal of Molecular Sciences, 22, Article 13064. https://doi.org/10.3390/ijms222313064
|
[33]
|
Gorrieri, G., Zara, F. and Scudieri, P. (2022) SLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease. Biomolecules, 12, Article 202. https://doi.org/10.3390/biom12020202
|
[34]
|
Corvol, H., Mésinèle, J., Douksieh, I.H., et al. (2018) SLC26A9 Gene Is Associated with Lung Function Response to Ivacaftor in Patients with Cystic Fibrosis. Frontiers in Pharmacology, 9, Article 828. https://doi.org/10.3389/fphar.2018.00828
|
[35]
|
De Paiva, A.C., Marson, F.A., Ribeiro, J.D., et al. (2014) Asthma: Gln27Glu and Arg16Gly Polymorphisms of the Beta2-Adrenergic Receptor Gene as Risk Factors. Allergy, Asthma & Clinical Immunology, 10, Article No. 8. https://doi.org/10.1186/1710-1492-10-8
|
[36]
|
Hart, M.A., Konstan, M.W., Darrah, R.J., et al. (2005) Beta 2 Adrenergic Receptor Polymorphisms in Cystic Fibrosis. Pediatric Pulmonology, 39, 544-550. https://doi.org/10.1002/ppul.20210
|
[37]
|
Wright, F.A., Strug, L.J., Doshi, V.K., et al. (2011) Genome-Wide Association and Linkage Identify Modifier Loci of Lung Disease Severity in Cystic Fibrosis at 11p13 and 20q13.2. Nature Genetics, 43, 539-546. https://doi.org/10.1038/ng.838
|
[38]
|
Corvol, H., Blackman, S.M., Boëlle, P.Y., et al. (2015) Genome-Wide Association Meta-Analysis Identifies Five Modifier Loci of Lung Disease Severity in Cystic Fibrosis. Nature Communications, 6, Article No. 8382. https://doi.org/10.1038/ncomms9382
|
[39]
|
Zhou, Y.-H., Gallins, P.J., et al. (2023) Genetic Modifiers of Cystic Fibrosis Lung Disease Severity: Whole-Genome Analysis of 7,840 Patients. American Journal of Respiratory and Critical Care Medicine, 207, 1324-1333. https://doi.org/10.1164/rccm.202209-1653OC
|